DDF acquisition
This article was originally published in The Rose Sheet
Executive Summary
North Castle Partners private equity firm acquires a controlling interest in DDF skin care marketer HDS Cosmetics Lab, company announces April 8. DDF's positioning is consistent with North Castle's focus on healthy living and aging, and will give the firm a foothold in the rapidly growing cosmeceutical segment, Greenwich, Conn. firm says. HDS Cosmetics Lab CEO Joseph Contorno will remain with the firm in his current position. DDF generated sales of approximately $40 mil. in 2003, HDS Cosmetics says. New financing of the firm will also be funded by Easton Hunt capital partners and Easton Hunt New York, affiliates of the Easton Capital Group...
You may also be interested in...
P&G buys HDS Cosmetics Lab
Procter & Gamble gains firm's Doctor's Dermatologic Formula (DDF) skin care line - designed for specific skin concerns such as anti-aging, acne, hyperpigmentation and sun protection - through an acquisition announced Jan. 22. Lauding DDF as a "leading dermatologist brand in the retail specialty channel [with] a strong following of loyal consumers," P&G says it will "infuse the line with a steady stream of innovation, add marketing expertise and leverage its global reach and go-to-market capability to drive future expansion." The move reflects P&G's sharpening focus on skin care as a key growth driver, company adds. P&G acquired the company from private equity firm North Castle Partners, which purchased a controlling interest in HDS in 2004 (1"The Rose Sheet" April 12, 2004, In Brief)...
DDF Sun Care Kits Will Bow In March To Treat Specific Skin Types
Doctor's Dermatologic Formula will add three new sun care kits to its lineup this spring, the firm said. The sets are customized to treat different skin types, DDF noted, unveiling the products during a Feb. 3 press event in New York City
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.